Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations.
Article Details
- CitationCopy to clipboard
D'Ambrosio D, Steinmann J, Brossard P, Dingemanse J
Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations.
Immunopharmacol Immunotoxicol. 2015 Feb;37(1):103-9. doi: 10.3109/08923973.2014.993084.
- PubMed ID
- 25519470 [ View in PubMed]
- Abstract
Ponesimod, a novel selective sphingosine-1-phosphate 1 receptor modulator in the development for the treatment of autoimmune diseases, dose-dependently reduced lymphocyte counts in peripheral blood of healthy subjects. It rapidly and transiently reduced the number of circulating T and B cells, but not natural killer cells. T lymphocyte subsets exhibited differential sensitivities with a maximum decrease from baseline ranging from 67% to 89% following high doses. Naive T cells were more sensitive than memory T cells. CD4(+) T cells were more sensitive than CD8(+) T cells or CD4(+)CD25(+) T regulatory cells. The differential effects on specialized T cell subsets may contribute to the immunomodulatory activity of ponesimod. The therapeutic potential of ponesimod has been recently shown in phase II studies of chronic plaque psoriasis and relapsing-remitting multiple sclerosis. Our data suggest that lymphocyte sequestration underlies the therapeutic potential of ponesimod in multiple autoimmune and chronic inflammatory diseases.
DrugBank Data that Cites this Article
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Ponesimod Sphingosine 1-phosphate receptor 1 Protein Humans YesAgonistModulatorRegulatorDetails